Y-mAbs Hosting Virtual Research and Development Day
06. Dezember 2021 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments
04. November 2021 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis
04. November 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021
28. Oktober 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended...
Y-mAbs’ 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA
07. Oktober 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Data to be Presented at SIOP 2021
16. September 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of...
Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China
13. September 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma
10. September 2021 09:00 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments
05. August 2021 16:01 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021
29. Juli 2021 16:05 ET
|
Y-mAbs Therapeutics, Inc
NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter ended June...